title: Recurrent central neurocytomas.
abstract: BACKGROUND
  Since the first description of Central neurocytomas (CNs) as a benign tumor entity in 1982, there has been great enthusiasm regarding the benign course and the curative surgical approach to this disease. The current study was performed to investigate the frequency of disease recurrence during long-term follow-up.
  
  
  METHODS
  A retrospective analysis of the medical files with emphasis on clinicoradiologic findings and histologic and immunohistochemical features was performed.
  
  
  RESULTS
  Between 1985-2003. surgical resection was performed in 14 patients with CNs ages 16-43 years (7 were female and 7 were male). Two patients (14%) died postoperatively and one patient had a malignant disease course (7%). In the remaining 11 patients, one patient with an incompletely resected CN had disease progression after 37 months but at the time of last follow-up had had stable disease for 10 years. In addition, the authors reported 5 patients with disease recurrence occurring at a median of 67 months after surgery (range, 51-79 months after surgery), all of which occurred after complete surgical resection was performed. The observation period for the remaining 5 patients was short (median of 34 months [range, 5-44 months]). Extensive histologic and immunohistochemical workup did not identify any significant prognostic parameters. The MIB-1 proliferation index ranged from 0.8-11% (median of 4.6%), but was reported to be 46.8% in the malignant transformed tumor. All patients with disease recurrence responded well to different forms of focal radiation therapy (gamma knife radiosurgery in three patients and interstitial irradiation in one patient) and for one patient with a recently detected recurrence, gamma knife radiosurgery was planned.
  
  
  CONCLUSIONS
  CNs appear to have a higher tendency to recur during long-term follow-up than previously reported, even after complete resection. Therefore, periodic neuroradiologic follow-up examinations should be considered mandatory in all patients, even after several years.
authors.affiliation: Neurosurgical Department, Medical University of Vienna, Vienna, Austria. alexander.bertalanffy@univie.ac.at
authors.forename: Alexander
authors.initials: A
authors.lastname: Bertalanffy
authors.forename: Karl
authors.initials: K
authors.lastname: Roessler
authors.forename: Oskar
authors.initials: O
authors.lastname: Koperek
authors.forename: Ellen
authors.initials: E
authors.lastname: Gelpi
authors.forename: Daniela
authors.initials: D
authors.lastname: Prayer
authors.forename: Engelbert
authors.initials: E
authors.lastname: Knosp
mesh_terms: D000293:Adolescent; D000328:Adult; D014408:Biomarkers, Tumor / Q000032:analysis; D001932:Brain Neoplasms / Q000175:diagnosis / Q000453:epidemiology* / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000453:epidemiology*; D018306:Neurocytoma / Q000175:diagnosis / Q000453:epidemiology* / Q000601:surgery; D012189:Retrospective Studies; D013997:Time Factors
chemical_list: D014408:Biomarkers, Tumor